Optos and Toku have reached an agreement to make Toku’s BioAge available to users of Optos Daytona, Monaco, MonacoPro, and California devices in the United States. The companies state that by incorporating the AI solution, BioAge, eye care professionals can expand their health and wellness insights without the need to replace existing hardware.¹

In the news release¹, Masayuki Numako, Director & Executive Vice President, Head of Healthcare Business Division at Optos spoke to the value this agreement can bring to providers saying, “We are delighted to offer our customers the ability to seamlessly integrate BioAge into their workflow. This collaboration allows eye care professionals to deliver greater value to their patients through a deeper understanding of their overall wellness.”

Ehsan Vaghefi, CEO, Toku also spoke to the power of this agreement, saying, “At Toku, our mission is to empower individuals with health insights that encourage proactive care and healthier lifestyles. Through this agreement with Optos, we are excited to make BioAge accessible to more than 20,000 eyecare practices across the United States equipped with ultra-widefield imaging devices. Together, we are combining the power of AI and retinal photography to help patients take charge of their overall wellness.”¹

What is BioAge?

Toku’s BioAge is an advanced AI solution that estimates a person’s biological age, a measure of overall health, by analyzing vascular and metabolic indicators visible in the retina. With a single pair of ultra-widefield retinal images, eye care providers can offer patients information that extends beyond ocular health and provides insights into systemic wellness.¹

The companies include the disclaimer that BioAge is intended for general wellness use and is not approved or cleared by the US Food and Drug Administration as a medical device.¹

About Optos

For more than 30 years, Optos has been the exclusive provider of 200-degree single-shot ultra-widefield retinal imaging systems to eye care professionals worldwide. With over 27,000 devices in use and supported by more than 3,000 clinical papers, Optos has also developed integrated ultra-widefield retinal imaging with optomap-guided Optical Coherence Tomography (OCT). Optos devices facilitate the early detection, management, and effective treatment of disorders and diseases evidenced in the retina such as retinal detachments and tears, glaucoma, diabetic retinopathy, and age-related macular degeneration.¹

About Toku, Inc.

Toku, Inc., specializes in converting routine eye exams to comprehensive health assessments by developing AI-powered tools. The company’s first commercialized product, BioAge, uses AI to analyze biometric markers in the retina to accurately identify an individual’s biological age. Toku’s second product, CLAiR, provides cardiovascular risk assessment and has received Breakthrough Device designation from the United States Food and Drug Administration; however, it is not yet approved for use in the US. ¹

Reference:

1. Optos and Toku Announce Agreement to Bring BioAge to Ultra-Widefield Retinal Imaging Devices. Optos. News Release. September 16, 2025. Accessed September 19, 2025. https://www.optos.com/press-releases/optos-toku-bioage-agreement/